UiPath (PATH) Price Target Increased by 15.84% to 15.99

Analysts raised UiPath's one-year average price target to $15.99 (up 15.84% from $13.80 on Nov. 14, 2025) with a target range of $12.91–$19.95, though the average target remains 14.37% below the recent close of $18.67. Institutional positioning shows 731 funds holding PATH (down 3 owners, -0.41% quarter-over-quarter) and total institutional shares fell 15.34% to 320,508K; the options put/call ratio is 0.26, indicating bullish options sentiment. Major holders include Polygon Management (16,950K shares, 3.74%, +19.04% vs prior filing), Vanguard Total Stock Market (12,560K, 2.77%), Senvest (10,862K, 2.39%), Bank of America (10,307K, 2.27%) and Vanguard Small-Cap (9,523K, 2.10%).

Analysis

Market structure: UiPath sits at the intersection of RPA/SaaS winners (enterprise automation buyers, cloud integrators) and losers (legacy IT services that enable manual work). Institutional data — 15% fewer institutional shares but a 7% rise in average portfolio weight — signals active rotation into higher conviction positions by some managers (Polygon +19%), while others trim; float/supply has risen short-term which increases pressure on the stock if demand softens. Options flow (put/call 0.26) shows short-dated bullishness that can amplify moves but is not a substitute for fundamental demand.

Risk assessment: Tail risks include a sharp enterprise IT spend pullback (revenue shock >15% YoY), rapid displacement by embedded AI in platforms, or large-customer churn (>10% ARR lost) — any would compress valuation by 30%+. Near-term (days–weeks) price is sensitive to flows and earnings whispers; medium-term (3–9 months) depends on ARR growth/renewal cadence; long-term (1–3 years) hinges on sustained ARR >15% and margin expansion to justify >$20. Hidden dependencies: customer concentration, SUITE integrations with major cloud vendors, and index/ETF rebalance mechanics can create non-fundamental volatility.

Trade implications: Tactical short if price sustains above $19 — target $13–16 within 3–6 months with a hard stop at $22.5; defensive long via capped-cost LEAP (Jan 2027 15/25 debit call spread) sized 1–2% to play an AI automation upside while limiting capital at risk. Income/entry tactics include selling 30–45 day cash-secured $15 puts up to 1% notional to collect premium/bootstrapped entry or selling covered calls at $20 if already long. For beta-neutral exposure, pair a PATH LEAP long with a short position in IGV (iShares Expanded Tech Software ETF) sized to net sector exposure.

Contrarian angle: Consensus (avg PT $15.99 vs $18.67 market) likely understates the optionality from AI-native automation wins — Polygon’s 19% accumulation is a non-trivial signal of differentiated fundamental conviction. The sell-side average embeds a ~14% downside from here; that may be overdone if two consecutive quarters show ARR acceleration >12% and net dollar retention stabilizes above 110% — a regime change that could re-rate the stock sharply higher. Conversely, a soft renewal quarter would rapidly validate the lower PT and create a squeeze candidate for short-covering.

Key Decisions for Investors

• Initiate a tactical short position in PATH sized 2–3% of portfolio if the stock trades >$19; set target $13–16 over 3–6 months and a stop-loss at $22.50 (≈20% above entry) to monetize analyst downgrade risk and institutional selling.
• Establish a conservative long exposure via Jan 2027 15/25 call debit spread (size 1–2% notional) to capture multi-quarter ARR re-acceleration upside while capping downside; unwind if two sequential quarters show ARR growth <10% or net dollar retention falls below 105%.
• Use options to generate yield or set entry: sell cash-secured 30–45 day $15 puts up to 1% notional to collect premium and acquire shares below consensus target, or if already long, sell 30–60 day $20 covered calls to improve carry (close if implied vol spikes >40%).
• Establish a beta-neutral pair: long PATH LEAP (Jan 2027 $15 call) and short proportional exposure to IGV (iShares Expanded Tech Software ETF) sized to neutralize sector beta; review after next earnings — reduce short-ETF leg if PATH shows >12% ARR growth quarter-over-quarter.